Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29940 | 0.95 | ACHE (0.56) | ACHETSHREPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL14328774 | 0.93 | EPHX1 (0.59) | ACHETSHREPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL10349440 | 0.93 | EPHX1 (0.59) | ACHETSHREPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL27357894 | 0.93 | EPHX1 (0.59) | ACHETSHREPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL8769221 | 0.93 | EPHX1 (0.59) | ACHETSHREPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL6332081 | 0.93 | EPHX1 (0.59) | ACHETSHREPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL8769636 | 0.93 | EPHX1 (0.59) | ACHETSHREPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL6332791 | 0.93 | EPHX1 (0.59) | ACHETSHREPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL8769159 | 0.93 | EPHX1 (0.59) | ACHETSHREPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL4458941 | 0.89 | ACHE (0.47) | ACHETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022178592-A1 | SOLID PHASE SYNTHESIS OF GLUTAMATE-UREA-LYSINE DERIVED (GUL DERIVED) PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETING CONJUGATES AND THEIR USE AS PRECURSORS FOR THERAPEUTIC AND / OR DIAGNOSTIC AGENTS | Telix International Pty Ltd (AU) | 2022-09-01 | — | — | WO | disclosed |
| US-20170306381-A1 | CELL LINES | ALLOZYNE, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9732367-B2 | Cell lines | MEDIMMUNE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| CN-102197023-B | Compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-12-16 | — | — | CN | disclosed |
| US-20150259721-A1 | CELL LINES | ALLOZYNE, INC. | 2015-09-17 | — | — | US | disclosed |
| US-8404650-B2 | Methods of treating cancer with doxazolidine and prodrugs thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-03-26 | — | — | US | disclosed |
| US-8101751-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-24 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20110135618-A1 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-06-09 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7605134-B2 | Pesticides | MERIAL LIMITED (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605134-B2 | Pesticides | MERIAL LIMITED (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1421094-B1 | 4\"-DEOXY-4\"-(S)-AMINO AVERMECTIN DERIVATIVES | MERIAL LTD (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-7407952-B2 | Reverse-turn mimetics and compositions and methods related thereto | MYRIAD GENETICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-0579102-B1 | Liquid chromatography stationary phases with reduced silanol interactions | WATERS INVESTMENTS LTD (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5374755-A | Silica substrate with silanol surface groups blocked by (substituted)dialkylcarbamates | MILLIPORE CORPORATION (US) | 1994-12-20 | — | — | US | disclosed |
| EP-0579102-A1 | Liquid chromatography stationary phases with reduced silanol interactions | WATERS INVESTMENTS LIMITED (US) | 1994-01-19 | — | — | EP | disclosed |
| US-4260552-A | INSECTICIDES, HERBICIDES | UNIROYAL, INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4160846-A | Method for controlling insects with tetrasubstituted organotin compounds | UNIROYAL, INC. (US) | 1979-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259721-A1 | CELL LINES | AARS1, LARS1, IARS1 | ACHE 4880/4885TSHR 563/4885EPHX1 4635/4885 |
| US-20110135618-A1 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | DNPEP, PEPD, PREP | ACHE 448/4885TSHR 3888/4885EPHX1 348/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ACHE 1324/4885TSHR 1567/4885EPHX1 1924/4885 |
| US-20170306381-A1 | CELL LINES | AARS1, LARS1, IARS1 | ACHE 4880/4885TSHR 563/4885EPHX1 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.